Cargando…
Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
BACKGROUND: Transformation to small cell lung cancer (SCLC) is a resistance mechanism of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LADC) patients treated with EGFR tyrosine kinase inhibitors (TKIs). Here, we describe the clinical characteristics and prognosis of these patie...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487822/ https://www.ncbi.nlm.nih.gov/pubmed/34490724 http://dx.doi.org/10.1111/1759-7714.14144 |
_version_ | 1784578034047647744 |
---|---|
author | Wang, Shouzheng Xie, Tongji Hao, Xuezhi Wang, Yan Hu, Xingsheng Wang, Lin Li, Yan Li, Junling Xing, Puyuan |
author_facet | Wang, Shouzheng Xie, Tongji Hao, Xuezhi Wang, Yan Hu, Xingsheng Wang, Lin Li, Yan Li, Junling Xing, Puyuan |
author_sort | Wang, Shouzheng |
collection | PubMed |
description | BACKGROUND: Transformation to small cell lung cancer (SCLC) is a resistance mechanism of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LADC) patients treated with EGFR tyrosine kinase inhibitors (TKIs). Here, we describe the clinical characteristics and prognosis of these patients and explore the treatment modes after transformation. METHODS: EGFR‐mutant LADC patients with SCLC transformation were retrospectively included in the study. Demographic and clinical data were collected. Survival outcomes and corresponding influential factors were analyzed. RESULTS: Twenty‐nine patients were included in the study. The median progression‐free survival (PFS) of patients who received first‐line EGFR‐TKIs was 13.1 months. The median time to SCLC transformation was 27.5 months. After transformation, the objective response rates of patients who received first‐line chemotherapy with or without EGFR‐TKIs were 43.8% and 37.5%, respectively. The median PFS of patients reveiving chemotherapy with EGFR‐TKIs was significantly longer than that of patients receiving chemotherapy without EGFR‐TKIs (5.2 vs. 3.0 months; HR, 0.19; 95% CI: 0.05–0.72; p = 0.014). However, there was no significant difference in median overall survival (OS) between patients who received chemotherapy with or without EGFR‐TKIs (14.8 vs. 13.0 months; p = 0.474). In the multivariate Cox proportional hazards regression analysis, both anti‐angiogenic treatment (HR, 0.04; 95% CI: 0.01–0.29; p = 0.001) and local radiotherapy (HR, 0.28; 95% CI: 0.08–0.97; p = 0.044) were significantly associated with better patient OS after transformation. CONCLUSIONS: Compared with chemotherapy alone, the combination of chemotherapy and EGFR‐TKIs as first‐line treatment after SCLC transformation can benefit patients in PFS but not in OS. However, anti‐angiogenic therapies and local radiotherapy can significantly prolong OS after transformation. |
format | Online Article Text |
id | pubmed-8487822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-84878222021-10-08 Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma Wang, Shouzheng Xie, Tongji Hao, Xuezhi Wang, Yan Hu, Xingsheng Wang, Lin Li, Yan Li, Junling Xing, Puyuan Thorac Cancer Original Articles BACKGROUND: Transformation to small cell lung cancer (SCLC) is a resistance mechanism of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LADC) patients treated with EGFR tyrosine kinase inhibitors (TKIs). Here, we describe the clinical characteristics and prognosis of these patients and explore the treatment modes after transformation. METHODS: EGFR‐mutant LADC patients with SCLC transformation were retrospectively included in the study. Demographic and clinical data were collected. Survival outcomes and corresponding influential factors were analyzed. RESULTS: Twenty‐nine patients were included in the study. The median progression‐free survival (PFS) of patients who received first‐line EGFR‐TKIs was 13.1 months. The median time to SCLC transformation was 27.5 months. After transformation, the objective response rates of patients who received first‐line chemotherapy with or without EGFR‐TKIs were 43.8% and 37.5%, respectively. The median PFS of patients reveiving chemotherapy with EGFR‐TKIs was significantly longer than that of patients receiving chemotherapy without EGFR‐TKIs (5.2 vs. 3.0 months; HR, 0.19; 95% CI: 0.05–0.72; p = 0.014). However, there was no significant difference in median overall survival (OS) between patients who received chemotherapy with or without EGFR‐TKIs (14.8 vs. 13.0 months; p = 0.474). In the multivariate Cox proportional hazards regression analysis, both anti‐angiogenic treatment (HR, 0.04; 95% CI: 0.01–0.29; p = 0.001) and local radiotherapy (HR, 0.28; 95% CI: 0.08–0.97; p = 0.044) were significantly associated with better patient OS after transformation. CONCLUSIONS: Compared with chemotherapy alone, the combination of chemotherapy and EGFR‐TKIs as first‐line treatment after SCLC transformation can benefit patients in PFS but not in OS. However, anti‐angiogenic therapies and local radiotherapy can significantly prolong OS after transformation. John Wiley & Sons Australia, Ltd 2021-09-06 2021-10 /pmc/articles/PMC8487822/ /pubmed/34490724 http://dx.doi.org/10.1111/1759-7714.14144 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Wang, Shouzheng Xie, Tongji Hao, Xuezhi Wang, Yan Hu, Xingsheng Wang, Lin Li, Yan Li, Junling Xing, Puyuan Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma |
title | Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma |
title_full | Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma |
title_fullStr | Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma |
title_full_unstemmed | Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma |
title_short | Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma |
title_sort | comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487822/ https://www.ncbi.nlm.nih.gov/pubmed/34490724 http://dx.doi.org/10.1111/1759-7714.14144 |
work_keys_str_mv | AT wangshouzheng comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma AT xietongji comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma AT haoxuezhi comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma AT wangyan comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma AT huxingsheng comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma AT wanglin comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma AT liyan comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma AT lijunling comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma AT xingpuyuan comprehensiveanalysisoftreatmentmodesandclinicaloutcomesofsmallcelllungcancertransformedfromepidermalgrowthfactorreceptormutantlungadenocarcinoma |